Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

*

Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK

*

Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK

Univ. Lille, INSERM UMR-S1172—Lille Neuroscience et Cognition, CHU Lille, FHU Precise, Lille, France

Neurology Center of San Antonio, San Antonio, TX, USA

Bern University Hospital and University of Bern, Bern, Switzerland

Fundacion IMABIS, Hospital Universitario Carlos Haya, Málaga, Spain

Barts and The London School of Medicine, Queen Mary University of London, London, UK

Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic

Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain

Department of Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain/Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain

Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Center of Clinical Neuroscience, Department of Neurology Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany

on behalf of the CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators
Corresponding Author:

AJ Coles Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Box 165, Level 5 Block A, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK.

*Co-first authors.

Comments (0)

No login
gif